Nanjing Leads Biolabs Co.,ltd

This study is testing an experimental drug called LBL-024 in people with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 396 adults aged 18 to 80 are taking part. The drug is given…

This study tests an experimental drug called LBL-024 combined with standard chemotherapy (cisplatin, gemcitabine) and bevacizumab in 140 people with advanced solid tumors. The goal is to see if the combination can shrink tumors and control the disease. Participants must be 18–75,…

This study tests a new drug called LBL-024 combined with the chemotherapy paclitaxel in people with ovarian cancer that has become resistant to platinum-based treatments. The trial involves 110 participants and aims to see if the combination can shrink tumors and delay disease pr…

This study tests a new drug called LBL-024, alone or combined with LBL-007 or toripalimab, in 200 people with advanced melanoma. The goal is to see if these treatments are safe and can shrink tumors. Participants receive the drugs through an IV, and doctors monitor side effects a…

This study tests an experimental drug called LBL-024 combined with standard chemotherapy and immunotherapy for people with advanced solid tumors. About 110 adults with good overall health will receive the treatment to see if tumors shrink or stop growing. The goal is to find a sa…

This study tests a new drug called LBL-024 combined with other medicines in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or stop them from growing. About 230 adults aged 18-75 will take p…

This study tests an experimental drug called LBL-024 combined with other cancer drugs (capecitabine, tislelizumab, and oxaliplatin) in 110 adults with advanced solid tumors. The goal is to see if the combination shrinks tumors and is safe. Participants must be in good overall hea…

This early-stage study tests a single injection of a new drug, LBL-047, in healthy adults and people with mild-to-moderate systemic lupus erythematosus (SLE). The main goal is to check safety and side effects. About 112 participants will receive either the drug or a placebo. This…

This study tests a new drug called LBL-024 combined with standard chemotherapy (etoposide plus platinum) as a first treatment for people with advanced neuroendocrine carcinoma. About 178 adults aged 18-75 will take part to see if the combination is safe and helps shrink tumors. T…

This study tests a new drug called LBL-024, either by itself or combined with chemotherapy (albumin-bound paclitaxel), in people whose triple negative breast cancer has come back or spread. The goal is to see if the drug can shrink tumors and control the disease. About 220 adults…

This study tests an experimental drug called LBL-034 in people whose multiple myeloma has returned or no longer responds to standard treatments. The trial has two phases: first, finding the safest dose, and then checking how well the drug shrinks tumors. About 342 adults will tak…